共 50 条
- [32] Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (01) : 101 - 109
- [34] T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (11): : 6653 - 6659
- [38] Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2002, 32 (01): : 30 - 36
- [39] PURIFICATION AND CHARACTERIZATION OF PAR O I, MAJOR ALLERGEN OF PARIETARIA-OFFICINALIS POLLEN [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1991, 96 (01): : 19 - 27